- Home
- DHAI vs RLYB Comparison
DHAI vs RLYB Comparison
Compare DHAI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- RLYB
- Stock Information
- Founded
- DHAI 2007
- RLYB 2018
- Country
- DHAI United States
- RLYB United States
- Employees
- DHAI N/A
- RLYB N/A
- Industry
- DHAI
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- DHAI
- RLYB Health Care
- Exchange
- DHAI NYSE
- RLYB Nasdaq
- Market Cap
- DHAI 49.1M
- RLYB 42.7M
- IPO Year
- DHAI N/A
- RLYB 2021
- Fundamental
- Price
- DHAI $0.49
- RLYB $0.75
- Analyst Decision
- DHAI
- RLYB Buy
- Analyst Count
- DHAI 0
- RLYB 5
- Target Price
- DHAI N/A
- RLYB $9.75
- AVG Volume (30 Days)
- DHAI 310.5K
- RLYB 70.1K
- Earning Date
- DHAI 02-14-2025
- RLYB 03-11-2025
- Dividend Yield
- DHAI N/A
- RLYB N/A
- EPS Growth
- DHAI N/A
- RLYB N/A
- EPS
- DHAI N/A
- RLYB N/A
- Revenue
- DHAI $69,573,000.00
- RLYB $598,000.00
- Revenue This Year
- DHAI N/A
- RLYB N/A
- Revenue Next Year
- DHAI N/A
- RLYB N/A
- P/E Ratio
- DHAI N/A
- RLYB N/A
- Revenue Growth
- DHAI 5.40
- RLYB N/A
- 52 Week Low
- DHAI $0.48
- RLYB $0.73
- 52 Week High
- DHAI $3.67
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- DHAI 31.78
- RLYB 37.62
- Support Level
- DHAI $0.48
- RLYB $0.73
- Resistance Level
- DHAI $0.69
- RLYB $0.84
- Average True Range (ATR)
- DHAI 0.09
- RLYB 0.07
- MACD
- DHAI -0.00
- RLYB -0.00
- Stochastic Oscillator
- DHAI 4.00
- RLYB 12.89
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.